2008
Evidence that senescent human prostate epithelial cells enhance tumorigenicity: Cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT
Bhatia B, Multani AS, Patrawala L, Chen X, Calhoun‐Davis T, Zhou J, Schroeder L, Schneider‐Broussard R, Shen J, Pathak S, Chang S, Tang DG. Evidence that senescent human prostate epithelial cells enhance tumorigenicity: Cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. International Journal Of Cancer 2008, 122: 1483-1495. PMID: 18059027, DOI: 10.1002/ijc.23222.Peer-Reviewed Original ResearchConceptsHuman prostate epithelial cellsNHP cellsProstate epithelial cellsCell fusionVivo tumorigenicityTumor cellsTumor developmentNormal human prostate epithelial cellsEpithelial cellsAR mRNA expressionCell-cell fusionProstate cancer cell linesPotential mechanismsGene expression analysisP16INK4a protein expressionModel cell systemGenomic stabilityLNCaP prostate cancerCancer cell linesExogenous p16Expression analysisProstate cancerSenescent fibroblastsProgenitor markersProstate tumorigenesis
2004
UV-Induced B-Cell Lymphomas in p53 Heterozygous Mice.
Miyahara Y, Kazimi N, Multani A, Pathak S, Chang S, Angkasekwinai Y, Qin X, Ullrich S. UV-Induced B-Cell Lymphomas in p53 Heterozygous Mice. Blood 2004, 104: 1370. DOI: 10.1182/blood.v104.11.1370.1370.Peer-Reviewed Original ResearchB-cell lymphomaP53 heterozygous miceHeterozygous miceLymph nodesTumor cellsBone marrowUV-induced skin cancerUV-irradiated miceNon-skin cancerB-cell originWild-type miceUseful animal modelCell linesSkin cancer inductionSystemic immunosuppressionIL-10Mature B cellsFS40 sunlampsAggressive tumorsLymphoid organsSubcutaneous injectionB7-1B7-2Spleen cellsLymphoid malignanciesTumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer
Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer. Cancer Research 2004, 64: 3198-3208. PMID: 15126360, DOI: 10.1158/0008-5472.can-03-3672.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsBreast NeoplasmsCDC2-CDC28 KinasesCell Cycle ProteinsCell DivisionCell Line, TumorCyclin ECyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27CyclinsEstradiolEstrogen Receptor ModulatorsFemaleFulvestrantG1 PhaseGenomic InstabilityHumansMiddle AgedMolecular WeightPolyploidyProtein IsoformsTransfectionTumor Suppressor ProteinsConceptsBreast cancer patientsPoor outcomeCancer patientsBreast cancerCyclin ELMW formsPoor clinical outcomeEffects of antiestrogensPotential therapeutic targetLow molecular weight isoformsCyclin-dependent kinase inhibitor p21Clinical outcomesAggressive diseaseSurrogate markerDisease progressionPathobiological mechanismsTherapeutic targetMolecular weight isoformsPatientsTumor cellsLMW isoformsTumorsPowerful predictorLow molecular weight formWeight isoforms